Navigation Links
MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting

ectable therapy, offering fast relief without injections. By providing rapid onset with a novel formulation of a proven compound (dihydroergotamine mesylate), MAP Pharmaceuticals seeks to meet the treatment needs of the large, underserved population of migraine sufferers with MAP0004.

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and neurological diseases. The Company has announced positive results from Phase 2 clinical trials in two development programs: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122, ljohnson@mappharma.com

Web site: http://www.mappharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:6/2/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock at a public offering price of ... of 1,764,705 shares to be sold by Nevro and ... stockholders, resulting in aggregate proceeds of approximately $90.0 million ...
(Date:6/2/2015)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), a ... products for the treatment of central nervous system disorders, ... Vanda,s President and CEO, will deliver a corporate presentation ... New York City on Thursday, June 4, ... presentation at the Jefferies Global Healthcare Conference will be ...
(Date:6/2/2015)... 2, 2015  Endo International plc (NASDAQ: ENDP ... that it has commenced an underwritten public offering of ... shares in the offering are to be sold by ... to the underwriters of the Offering an option, exercisable ... of the final prospectus supplement, to purchase an additional ...
Breaking Medicine Technology:Nevro Announces Pricing of Upsized Public Offering of Common Stock 2Nevro Announces Pricing of Upsized Public Offering of Common Stock 3Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 2Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 3Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 4
... VIVUS, Inc. (NASDAQ: VVUS ) today ... accepted for review the company,s new drug application (NDA) for ... dysfunction (ED). The target date for the FDA to complete ... In previously announced results from the pivotal phase 3 trials, ...
... Sept. 1, 2011 Lung Cancer Alliance ... of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) ... on data from two clinical trials, both of which ... Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma ...
Cached Medicine Technology:VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction 2VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction 3New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population 2
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations ... expand urgent care services in Los Angeles County. ... of California Board of Regents and the Exer Board ... to purchase a minority share of four existing Exer ... and Northridge and creates opportunity to grow and develop ...
(Date:6/2/2015)... New Jersey (PRWEB) June 02, 2015 ... (Horizon BCBSNJ) announced today that its Walking and Wellness ... Classic Presented by Acer, has raised another $3,000 for ... Natalie Gulbis undertook the challenge, recording 32,000 steps on ... at Stockton Seaview Hotel & Golf Club in Galloway ...
(Date:6/2/2015)... 2015 Bitscape Infotech today announced it ... Worldwide Small and Midsized Cloud Solutions Award. The company ... partners for demonstrating excellence in innovation and implementation of ... comes as no surprise to us as we feel ... at worldwide level by Microsoft. We will continue to ...
(Date:6/2/2015)... June 02, 2015 “ Radaris ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... data they need on a person. , According to Psychology ... even goes on to explain that curiosity is a part ...
(Date:6/2/2015)... France, and Dallas, TX, USA (PRWEB) June 02, 2015 ... innovative nano and microsystems, is deploying its growth strategy ... applications, focusing on BioMEMS: “In Yole Développement’s May 2015 ... the BioMEMS market will grow sharply and reach $6.6B ... & Sensors at Yole Développement . , The ...
Breaking Medicine News(10 mins):Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 3Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:Tronics Aims to Benefit from Major Growth of Sensors and Related Technologies for Healthcare Applications 2
... about half of women age 65 and older would be ... rate for women falls to 12 percent. These facts ... in the latest installment of the Public Policy & Aging ... Society, the public policy branch of The Gerontological Society of ...
... Reporter , THURSDAY, Dec. 16 (HealthDay News) -- Federal ... drug Avastin to fight breast cancer, citing the medication,s ... serious side effects. But the recommendation, announced by ... news conference, will not immediately affect breast cancer patients, ...
... The American Heart Association has recognized UC Irvine Healthcare,s ... patients. The Get With The Guidelines Heart Failure ... achieved at least 85 percent compliance for one year with ... medical center,s compliance rate was 96 percent. The "Plus" designation ...
... December 16, 2010 The Elsevier Foundation has ... Innovative Libraries in Developing Countries program, committing over ... developing countries. The 2010 grant recipients were selected ... potential for impact in the developing world. The ...
... World Health Organization set a target for the influenza vaccination ... population and an increase to more than 75% by 2010. ... old German states. In the current issue of Deutsches ... 845󈞞) the working group around Annicka M. Reuss presents rates ...
... Reporter , THURSDAY, Dec. 16 (HealthDay News) -- Researchers ... -- the part of the brain believed to generate ... improve treatment for post-traumatic stress disorder (PTSD) and other ... confirming that the almond-shaped structure is crucial for triggering ...
Cached Medicine News:Health News:Brief clarifies Social Security's value for women 2Health News:FDA Advises Against Avastin as Treatment for Breast Cancer 2Health News:FDA Advises Against Avastin as Treatment for Breast Cancer 3Health News:UC Irvine Medical Center recognized for heart failure program 2Health News:Elsevier Foundation announces 2010 grants for libraries in developing countries 2Health News:Brain Anomaly Leaves Woman Without Fear 2Health News:Brain Anomaly Leaves Woman Without Fear 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: